INmune Bio (NASDAQ:INMB) Upgraded at Lucid Cap Mkts

INmune Bio (NASDAQ:INMB) was upgraded by stock analysts at Lucid Cap Mkts from a “hold” rating to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Wall Street Zen upgraded shares of INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, INmune Bio presently has an average rating of “Hold” and a consensus target price of $8.00.

INmune Bio Trading Up 10.9%

INmune Bio stock opened at $1.42 on Wednesday. INmune Bio has a 52 week low of $1.16 and a 52 week high of $11.64. The stock has a market cap of $37.75 million, a price-to-earnings ratio of -0.67 and a beta of 0.77. The company’s 50-day moving average price is $1.49 and its two-hundred day moving average price is $1.72.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. XTX Topco Ltd raised its position in INmune Bio by 240.9% in the second quarter. XTX Topco Ltd now owns 125,847 shares of the company’s stock worth $291,000 after acquiring an additional 88,928 shares in the last quarter. Westside Investment Management Inc. boosted its position in shares of INmune Bio by 384.0% during the 3rd quarter. Westside Investment Management Inc. now owns 103,450 shares of the company’s stock valued at $214,000 after purchasing an additional 82,075 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of INmune Bio by 1,042.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company’s stock worth $169,000 after purchasing an additional 66,700 shares during the last quarter. State Street Corp grew its stake in shares of INmune Bio by 22.3% in the 4th quarter. State Street Corp now owns 347,259 shares of the company’s stock worth $542,000 after purchasing an additional 63,426 shares during the last quarter. Finally, Jain Global LLC bought a new stake in shares of INmune Bio in the 4th quarter worth approximately $66,000. 12.72% of the stock is owned by institutional investors and hedge funds.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.